Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

In new research on patients with lupus nephritis, low-grade proteinuria does not predict improved renal outcomes or treatment responses, while 

 predicts renal function decline in patients who relapse.

Study investigator Nan Shen, MD, PhD, a distinguished professor of medicine at Shanghai JiaoTong University, and colleagues, aimed to “investigate the clinical characteristics, renal pathology treatment responses, and renal outcomes of lupus nephritis (LN) patients with different levels of baseline proteinuria.”

A previous 12-month study identified proteinuria as the strongest predictor of long-term renal outcomes in lupus nephritis compared with serum creatinine or urinary red blood cells.

 However, whether patients with low-grade proteinuria at baseline experience better clinical or histologic outcomes over time has remained unclear.

In lupus nephritis research, a 30%-40% decline in eGFR over several years is often used as a surrogate endpoint for long-term kidney function deterioration, allowing investigators to quantify clinically meaningful loss of renal function within a shorter follow-up period. In contrast, glomerulosclerosis represents a biopsy-based chronicity marker reflecting structural scarring present at baseline. Analyzing functional decline, eGFR loss, and structural damage associated with glomerulosclerosis can help clarify whether baseline proteinuria levels or chronicity features predict long-term renal outcomes.

In this longitudinal cohort study, investigators aimed to understand the association between proteinuria levels at baseline and clinical characteristics, renal pathology treatment responses, and renal outcomes of patients with lupus nephritis. The analysis incorporated chronicity markers such as glomerulosclerosis to identify predictors of long-term decline.

Shen and colleagues stratified patients by baseline proteinuria levels: low-grade (<1 g/24 h) and high-grade (≥1 g/24 h), in addition to disease onset status, incident or relapsing. At weeks 26 and 52, renal treatment responses were assessed by overall, complete, and primary efficacy renal response. By 156 weeks, investigators used Cox proportional hazards regression and Kaplan–Meier analyses to evaluate predictors of time to the first 30% and 40% eGFR decline as surrogate endpoints of long-term kidney disease progression.¹

The study included 239 patients with biopsy-proven lupus nephritis. Of these, 17.6% of participants had low-grade proteinuria levels (n = 42), and 82.4% had high-grade (n = 197). Additionally, investigators identified 51% of patients with incident lupus nephritis, and 49% had relapsing.

Upon analysis, investigators noted a decreased incidence of urinary sediments, an increased frequency of class V, and a decreased renal pathology activity index in the <1 group compared to the ≥1 group. These groups exhibited similar chronicity index, as well as similar overall remission rates at week 26 and 52.

At 156 weeks, investigators were able to observe an equivalent risk of 30% or 40% eGFR decline in patients with low-grade proteinuria compared with those with high-grade proteinuria. Investigators also evaluated renal pathology features. According to their findings, glomerulosclerosis independently predicted long-term renal deterioration in relapsing but not incident lupus nephritis.

“These results underscore the importance of early biopsy, personalized therapy, and close monitoring, supported by non-invasive biomarkers for risk assessment,” concluded investigators.

Shen Y, Peng J, Dai D, et al. Low‐Grade Proteinuria Does Not Predict Favorable Outcomes in Lupus Nephritis: A Longitudinal Cohort Study. Arthritis & Rheumatology. Published online November 28, 2025. doi:

Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort. 

Articles

Low-grade proteinuria in lupus nephritis patients does not predict improved renal outcomes or treatment responses, while glomerulosclerosis is a significant predictor of renal function decline in relapsing patients. A study involving 239 patients stratified by proteinuria levels and disease onset status found similar remission rates and chronicity indices between low-grade and high-grade proteinuria groups. However, glomerulosclerosis independently predicted long-term renal deterioration in relapsing lupus nephritis. These findings highlight the importance of early biopsy, personalized therapy, and non-invasive biomarkers for effective risk assessment and management.

A longitudinal cohort study shows a lack of correlation between decreased proteinuria levels and improved treatment, renal responses in patients. 


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Low-Grade Proteinuria Not Tied to Improved Renal Outcomes in Lupus Nephritis

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology and NeurologyLive, and for quickly transforming acquisitions into high-functioning business units. Follow him on X @

New 52-week data from the phase 3 VERIFY study continue to strengthen the case for rusfertide as a potential first-in-class therapy for patients with polycythemia vera (PV). Presented at the 

, the updated results demonstrate sustained hematocrit control below 45%, high rates of phlebotomy ineligibility, and a consistent safety profile for the hepcidin mimetic across both the randomized and open-label portions of the trial.

"Rusfertide met the primary and all 4 secondary end points in VERIFY from baseline to week 32 and continued to provide durable, sustained control of hematocrit below 45% and phlebotomy ineligibility through week 52," lead investigator Andrew Kuykendall, MD, at Moffitt Cancer Center in the Department of Malignant Hematology, said during a presentation of the results. "After 52 weeks of treatment in VERIFY, rusfertide was well tolerated with a safety profile that was consistent with prior observations."

The VERIFY study enrolled patients receiving standard-of-care PV management, defined as phlebotomy with or without cytoreductive therapy, and randomized them 1:1 to rusfertide or placebo for 32 weeks (part 1a). After the primary end-point assessment window at weeks 20 to 32, patients in the placebo arm crossed over to receive open-label rusfertide plus standard therapy through week 52 (part 1b). Durability of hematocrit control and phlebotomy independence were the key measures in the extension period.

The newly reported findings show that patients maintained on rusfertide experienced continued benefit, and those who switched from placebo rapidly caught up. Among participants who received rusfertide throughout, the rate of phlebotomy ineligibility increased from 76.9% at week 32 to 84.1% at week 52. For patients who switched from placebo to rusfertide, the phlebotomy ineligibility rate rose from 32.9% to 77.9% during the same timeframe. Hematocrit levels declined quickly in the crossover cohort by week 52, both groups achieved similar levels of control.

"Rusfertide lowered hematocrit levels without exacerbating systemic iron deficiency," said Kuykendall.

During the randomized period (part 1a), rusfertide showed superiority over placebo across all major clinical outcomes. Hematocrit control below 45% was achieved in 62.6% of patients receiving rusfertide versus 14.4% on placebo (

 <.0001). Patients in the rusfertide arm required far fewer phlebotomies, with a mean of 0.5 versus 1.8 for placebo (

 <.0001). Patient-reported outcomes also favored rusfertide, including improvements in fatigue and symptom burden. On the PROMIS Fatigue SF-8a, patients receiving rusfertide reported a 1.78-point decline in fatigue compared with a slight increase in the placebo group.

Baseline characteristics were well balanced between arms in part 1a. In the extension, the median patient age was 57 years, and the majority were male. Nearly half of participants met criteria for high-risk PV, defined by age ≥60 years and/or a history of thromboembolic events. Use of cytoreductive agents remained consistent between study phases, with hydroxyurea as the most common therapy.

Physiologic markers tracked throughout the study demonstrated biologic activity consistent with hepcidin mimetic therapy. Ferritin levels remained low and unchanged for placebo recipients in the randomized phase and increased steadily once patients crossed over to rusfertide. Transferrin levels decreased while transferrin saturation and serum iron rose modestly, suggesting improved iron homeostasis without indications of worsening systemic iron deficiency. Leukocyte counts remained stable and platelet counts showed modest improvement in rusfertide-treated patients.

Safety findings remained favorable and aligned with earlier trial experience. At data cutoff, 86.7% of patients continued receiving open-label rusfertide. Discontinuations were infrequent: 7.5% during randomized treatment and 2.6% in the open-label phase. Most treatment-emergent adverse events (TEAEs) were grade 1 or 2. Injection-site reactions were the most common TEAE, occurring in more than half of rusfertide-treated patients during the randomized portion but decreasing notably between weeks 32 and 52 among those who continued treatment.

Secondary malignancies were less common in the rusfertide group than in the placebo group in part 1a (3 vs 8 events) and remained low in part 1b following crossover.

"Optimistically, you can see that some of the injection site reactions actually go down in the rusfertide arm from week 32 to 52, suggesting it may lessen over time," said Kuykendall.

A regulatory submission for rusfertide in PV is planned, supported by VERIFY and results from the REVIVE trial, in which rusfertide achieved a 60% response rate compared with 17% for placebo. VERIFY parts 2 and 3 will continue to evaluate long-term efficacy, safety, and treatment durability over multiple years. 

Results from REVIVE also support rusfertide's efficacy.

Kuykendall A, Bankar A, Pettit K, et al. Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study. Blood. 2025;146(Supplement 1):abstract 81. doi:10.1182/blood-2025-8.

Kremyanskaya M, Kuykendall AT, Pemmaraju N, et al. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. 

New data from the phase 3 VERIFY study reinforce rusfertide's potential as a first-in-class therapy for polycythemia vera (PV). The study demonstrated sustained hematocrit control below 45%, high phlebotomy ineligibility rates, and a consistent safety profile. Patients on rusfertide showed improved outcomes compared to placebo, with significant reductions in hematocrit levels and phlebotomy needs. The study also highlighted improvements in fatigue and symptom burden. Safety findings were favorable, with most adverse events being mild. A regulatory submission for rusfertide in PV is planned, supported by these findings.

Rusfertide shows promising results as a first-in-class therapy for polycythemia vera, demonstrating sustained hematocrit control and safety in recent studies.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hematology

Rusfertide Maintains Hematocrit Control Through 52 Weeks in VERIFY

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

While largely a quiet month for endocrinology, November 2025 was not without its important updates. There were no significant approvals from the 

, but glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have continued their advances into other condition centers such as nephrology and cardiology. Additionally, Novo Nordisk has had a rollercoaster month, between the failure of semaglutide to significantly reduce 

 has collected 5 of the most impactful headlines to come out of endocrinology in the last month. Check them out below to catch up on any news you might have missed.


Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo


On November 25, 2025, Novo Nordisk announced the success of their phase 2 clinical trial of amycretin, an investigative drug administered once-weekly subcutaneously or once-daily orally, in triggering weight loss and HbA1c reductions in patients with T2D. Based on these positive results, the company has also announced its intention to begin a phase 3 program at some point in 2026.


Investigative Amylin Agonist Eloralintide Proves Superiority to Placebo in Weight Management


Eloralintide displayed superior mean weight reductions versus placebo among adult patients with obesity and ≥1 weight-related comorbidity. The once-weekly selective amylin receptor agonist has the capacity to decrease calorie intake, which clinicians attribute to potential effects on satiety. Eloralintide is also under investigation both alone and with tirzepatide for weight management in adults with overweight or obesity and T2D.


Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes


A recent meta-analysis has highlighted a connection between semaglutide and favorable safety profiles in patients with 

, regardless of the presence of diabetes. During 5 randomized clinical trials, semaglutide was shown to lower the risk of major adverse cardiovascular events, kidney-related complications, and cardiovascular mortality. Investigators used these data to highlight the need for enhanced generalizability of GLP-1 data in nephrological diseases.


Diabetes Dialogue: Updates on Dexcom G7 and Semaglutide Pricing


In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed Dexcom’s announcement of the 15-day G7 sensor, which launched on December 1 through durable medical equipment channels and is planned to launch in pharmacies in January of 2026. The new sensor will integrate with the existing app platform and maintain the same accuracy profile, with a 15.5-day life via a built-in 12-hour grace period. Additionally, Isaacs and Bellini covered the significant price changes to Ozempic and Wegovy, with both drugs across all doses dropping to $199 for the first 2 months and $349 thereafter.


Diabetes Dialogue: Semaglutide Falls Short in Alzheimer Disease, Tirzepatide Shows Promise in T1D


In this episode, Isaacs and Bellini discuss Novo Nordisk’s negative results after the Evoke and Evoke+ phase 3 trials, both of which failed to show a reduction in disease progression speed in Alzheimer’s disease with oral semaglutide 14 mg. Although both trials saw improvements in related biomarkers, their failure to slow Alzheimer’s progression resulted in Novo Nordisk discontinuing a planned 1-year extension. However, these disappointing results are offset up the success of the TIRTLE phase 2 trial, which showed tirzepatide’s benefit in weight loss in adult patients with 

. Tirzepatide also improved glycemic control, reduced HbA1c, and decreased total daily insulin dose relative to placebo, all without significant adverse events.

November 2025 saw significant developments in endocrinology, despite no major FDA approvals. GLP-1 receptor agonists are expanding into nephrology and cardiology. Novo Nordisk experienced mixed results, with semaglutide failing to impact Alzheimer's progression, but amycretin showing promising weight loss outcomes in type 2 diabetes. Eloralintide demonstrated superior weight management, and semaglutide offered cardiorenal benefits in chronic kidney disease. Updates included Dexcom G7's launch and semaglutide pricing changes. Tirzepatide showed promise in type 1 diabetes, despite semaglutide's disappointing Alzheimer’s trial results.

Catch up with major trial results, key clinician insights, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

5 Endocrinology Headlines You Missed in November 2025

Naeem Bhojani, MD, associate professor and clinical researcher at the University of Montreal.

Stern is a urologist and director of the endourology fellowship program at Mayo Clinic in Phoenix, Arizona.

Modernizing Kidney Stone Treatment: Devices, Data, and Clinical Impact

Kidney stones are an increasingly common public health problem, with notable increases observed in women

 Myriad treatment options exist, ranging from extracorporeal shock wave lithotripsy to ureteroscopy to percutaneous nephrolithotomy. A challenge for clinicians is removing enough of a patient’s stone burden and residual fragments as possible to avoid repeat procedures.

In recent years, there has been an explosion of innovative technology to enhance the safety and efficiency of stone treatment. In this video series, which can be viewed in full on HCPLive sister brand 

, urologists Karen L. Stern, MD, and Naeem Bhojani, MD, FRCSC, do a deep dive into these technologies, highlighting their pros and cons, learning curve, and future considerations.

Suction’s effect on treatment algorithms

The discussion, which is included in HCPLive’s 

, begins with a reflection on how quickly technology in endourology has accelerated. Only a few years ago, suction-assisted ureteroscopy was considered an unrealized aspiration. More recently, however, the field has been inundated with novel devices and refinements, forcing clinicians to evaluate how best to incorporate them. According to Stern and Bhojani, this rapid influx of innovation has allowed surgeons to take on larger stones ureteroscopically and has created the perception—supported by clinical experience—that stone-free rates and procedural safety are improving. They acknowledge that formal classifications of stone-free outcomes do not always mirror these impressions, yet their day-to-day practice suggests meaningful gains.

They emphasize that suction technology is only one part of a broader wave of progress. Enhanced scopes and major advancements in laser platforms, such as thulium fiber systems and refined pulse modulation, have improved efficiency in dust production and visibility during surgery. Meanwhile, the trend toward smaller scopes aids maneuverability and access. Together, these tools have arrived at a moment when the field was grappling with the limitations of traditional ureteroscopy, especially the realization that many patients were not as stone-free as surgeons previously assumed. This discrepancy served as a major motivator to explore suction-based methods, which now consistently outperform conventional approaches.

The conversation also touches on intrarenal pressure, an aspect of ureteroscopy that has become easier to assess thanks to new scopes capable of real-time monitoring. The introduction of suction has shown a favorable impact on these measurements by facilitating continuous fluid removal, helping maintain lower pressures even during high-flow irrigation. Although the full clinical implications are still being understood, parallels from percutaneous surgery—where suction reduces infections and postoperative complications—suggest similar benefits may emerge for ureteroscopy. The speakers highlight early data from their own work showing that, despite high irrigation rates, suction systems effectively keep pressures down through both passive and active fluid evacuation.

Chen KW, Meskawi M, Miller LE, et al. Trends in kidney stone prevalence among U.S. adults: a concerning contemporary gender analysis from the NHANES database. 

Tasian GE, Ross ME, Song L, et al. Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. 

Videos

Explore the latest advancements in kidney stone treatment, focusing on suction technology and its impact on surgical outcomes and patient safety.

This Year In Medicine

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Welcome back to our recap of this month's news and updates from the 

November brought a series of impactful FDA decisions spanning rare disease, pediatrics, neuromuscular disorders, and cardiometabolic care—each marking a meaningful expansion in therapeutic options for historically underserved patient populations. The month opened with the approval of doxycitine and doxribtimine (Kygevvi), the first treatment for thymidine kinase 2 deficiency, offering survival and functional benefits in an ultra-rare mitochondrial disorder with no prior therapies. Soon after, linaclotide became the first FDA-approved option for pediatric irritable bowel syndrome with constipation (IBS-C) in patients ≥7 years old, supported by efficacy signals consistent with adult outcomes. Mid-month, the agency issued significant safety-driven changes to ELEVIDYS, restricting its use to ambulatory patients with Duchenne muscular dystrophy (DMD) and adding a Boxed Warning following reports of acute liver failure in non-ambulatory recipients.

Regulators also advanced innovation in lipid and renal disease. The approval of plozasiran introduced the first apoC-III–targeting siRNA therapy for familial chylomicronemia syndrome, offering meaningful reductions in triglycerides, apoC-III, and pancreatitis risk with quarterly dosing. Closing the month, sibeprenlimab received accelerated approval for IgA nephropathy after demonstrating a more than 50% placebo-adjusted reduction in proteinuria at one year, adding momentum to a rapidly evolving treatment landscape ahead of confirmatory eGFR data. Collectively, these decisions signal an FDA increasingly focused on precision mechanisms and high-need populations across a diverse therapeutic spectrum. Here’s a concise overview of the key FDA decisions and updates from November 2025.

Want to hear from the experts? Look for our Related Content links underneath blurbs for insight into how this decision might influence practice moving forward.

FDA Approves Kygevvi, First Treatment for Thymidine Kinase 2 Deficiency

On November 3, 2025, UCB announced the FDA approved doxycitine and doxribtimine (Kygevvi) as the first therapy for thymidine kinase 2 deficiency (TK2d). Based on phase 2 clinical data, retrospective analyses, and an expanded access program, Kygevvi demonstrated improved survival and functional outcomes, including markedly lower mortality compared with untreated patients. The combined nucleoside therapy supports mitochondrial DNA replication and skeletal muscle function in this ultra-rare mitochondrial disorder.

FDA Approves Linaclotide (Linzess) Capsules for Pediatric IBS-C

On November 5, 2025, Ironwood Pharmaceuticals announced the FDA approved linaclotide (Linzess) for pediatric patients ≥7 years of age with irritable bowel syndrome with constipation (IBS-C), making it the first therapy authorized for IBS-C in this age group. Based on extrapolated adult efficacy data and a 12-week randomized pediatric trial, linaclotide 145 mcg once daily demonstrated reductions in abdominal pain and increases in spontaneous bowel movements consistent with adult outcomes. The safety profile was similar to that observed in adults, with diarrhea reported as the most common adverse event.

FDA Issues New Boxed Warning, Limiting ELEVIDYS to Ambulatory DMD

On November 14, 2025, the FDA announced new safety warnings and labeling revisions for delandistrogene moxeparvovec-rokl (Elevidys), restricting its indication to ambulatory patients with Duchenne muscular dystrophy.

Based on postmarketing safety reports, including fatal cases of acute liver failure in non-ambulatory recipients, the agency added a Boxed Warning for serious liver injury and mandated a postmarketing observational study with serial liver function monitoring. Updated guidance includes enhanced recommendations for hepatic and cardiac monitoring, cautions regarding corticosteroid-associated risks, and new contraindications for certain patient populations.

FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome

On November 18, 2025, Arrowhead Pharmaceuticals announced the FDA approved plozasiran (Redemplo) for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). Based on the phase 3 PALISADE trial and supportive phase 2 SUMMIT data, plozasiran significantly lowered fasting triglycerides and apoC-III levels and reduced acute pancreatitis risk, with dosing once every 3 months. The small-interfering RNA therapeutic demonstrated a favorable tolerability profile and represents the first approved therapy targeting apoC-III reduction for FCS.

RX Review: Leveraging siRNA in FCS Management

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

On November 25, 2025, Otsuka Pharmaceutical announced the FDA approved sibeprenlimab (Voyxact) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Based on results from the phase 3 VISIONARY trial, sibeprenlimab produced a 54.3% placebo-adjusted reduction in 24-hour urine protein-to-creatinine ratio after 12 months, with consistent effects across clinical subgroups. The APRIL-targeting antibody adds to the growing therapeutic landscape for IgA nephropathy and received accelerated approval pending full 2-year eGFR results expected in 2026.

Kidney Compass: Sibeprenlimab and the VISIONARY Trial, with Vlado Perkovic, MBBS, PhD, at ERA 2025

November saw significant FDA decisions enhancing therapeutic options for underserved populations, including rare diseases, pediatrics, and cardiometabolic care. Key approvals included Kygevvi for thymidine kinase 2 deficiency, linaclotide for pediatric IBS-C, and plozasiran for familial chylomicronemia syndrome. Safety updates for ELEVIDYS restricted its use to ambulatory Duchenne muscular dystrophy patients. Sibeprenlimab received accelerated approval for IgA nephropathy, marking progress in precision medicine. These decisions reflect the FDA's focus on precision mechanisms and high-need populations across diverse therapeutic areas.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

FDA News

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Dyslipidemia

5 FDA Headlines You Missed in November 2025

Chari Cohen, DrPH, MPH, is the President of the Hepatitis B Foundation.

Cohen cites past failures with risk-based hepatitis B vaccination and voices concerns about the CDC APIC vote for individual-based decision-making.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Clinical Concerns Over the ACIP Infant Hepatitis B Vaccine Decision, With Chari Cohen, DrPH, MPH

a psychiatrist and Chief Medical Officer at HMNC Brain Health

As the FDA strengthens AI standards after its recent meeting, a new AI-assisted genetic tool shows promise for pinpointing patients who may respond to a vasopressin blocker.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

New Genetic Tool Shows Promise for Targeted MDD Treatment, With Hans Eriksson, PhD, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The 8-3 APIC vote recommends individual-based decision-making for HBV vaccination in infants born to women who test negative for the virus.

CDC Changes Infant Hepatitis B Vaccine Recommendation

Decreased serum albumin levels can be a tool for predicting the risk of cancer and mortality in patients undergoing hemodialysis. 


Chronic Kidney Disease

Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis

Arun Chandra, MD, is an electrophysiology fellow at NewYork-Presbyterian Hospital and the clinical lead for Prevounce Health.

Remote patient monitoring revolutionizes cardiovascular care, enhancing preventive strategies, patient engagement, and outcomes through advanced technology and AI integration.

Evolving Evidence Supporting Remote Patient Monitoring in Cardiology

Findings suggest people with reduced kidney function have higher levels of Alzheimer’s biomarkers in their blood but not an increased risk of dementia.


Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Impaired Kidney Function Linked to Alzheimer’s Biomarkers But Not Dementia

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

This randomized study explored a lower-cost, ambient-light, nonpolarized dermatoscope and its clinical utility in patient-performed teledermoscopy.

More Costly, Polarized Dermatoscope Results Compared to Nonpolarized Dermatoscope

The panel reviews the two major therapeutic strategies for treating ATTR-CM: transthyretin (TTR) silencers and stabilizers. Stabilizers work by binding to the TTR protein and preventing it from misfolding into amyloid fibrils, helping maintain the protein’s native structure. Silencers, by contrast, act at the genetic level to reduce the production of TTR protein in the liver through RNA interference or antisense mechanisms. Together, these approaches aim to reduce amyloid formation and slow disease progression.
The experts note that patients are often highly informed and eager to understand the differences between these therapies. They emphasize the importance of clear, patient-centered discussions that explain how the treatments work, why both options exist, and how therapy selection may depend on disease stage, phenotype, genetic background, and emerging clinical evidence. As research evolves, clinicians continue to refine how these mechanisms complement one another and how combination or sequential strategies may shape future care.


Video Series

Mechanistic Roles of Transthyretin Silencers and Stabilizers in ATTR-CM

Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.

Selectivity of TYK2 Inhibition in Psoriasis

In this episode, the panelists focus on the IL-23 and IL-17 pathways and their influence on inflammation control and psoriatic arthritis (PsA) prevention. The experts explain that IL-23 sits at the top of the inflammatory cascade, driving Th17 cell activation and downstream cytokine release. They note that inhibiting IL-23 can lead to long-term immunologic remission and possibly modify PsA progression, given its infrequent dosing and favorable safety profile. The discussion compares IL-23 and IL-17 inhibition, highlighting that while IL-23 blockade targets disease upstream, IL-17 acts as the “enforcer” cytokine driving local joint and skin inflammation. The panelists review emerging data showing that dual inhibition of IL-17A and IL-17F, as achieved with newer biologics, may provide more robust and durable skin clearance than targeting IL-17A alone. They conclude that deeper inflammation control through these pathways could reduce PsA risk and sustain long-term disease remission.

Latest News

Low-Grade Proteinuria Not Tied to Improved Renal Outcomes in Lupus Nephritis

Rusfertide Maintains Hematocrit Control Through 52 Weeks in VERIFY

5 Endocrinology Headlines You Missed in November 2025

Modernizing Kidney Stone Treatment: Devices, Data, and Clinical Impact

5 FDA Headlines You Missed in November 2025